458 related articles for article (PubMed ID: 29341283)
1. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.
Masuda Y; Tatsuno K; Kitano S; Miyazawa H; Ishibe J; Aoshima M; Shimauchi T; Fujiyama T; Ito T; Tokura Y
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1456-1460. PubMed ID: 29341283
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Photosensitivity with Decreased Treg Cells in a Patient with Mycosis Fungoides Treated with Anti-CC Chemokine Receptor 4 Antibody Mogamulizumab.
Tatsuno K; Sano T; Fukuchi K; Kuriyama S; Aoshima M; Kasuya A; Ikeya S; Fujiyama T; Ito T; Tokura Y
Acta Derm Venereol; 2016 Mar; 96(3):420-1. PubMed ID: 26463269
[No Abstract] [Full Text] [Related]
3. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous T-cell lymphoma.
Lansigan F; Choi J; Foss FM
Hematol Oncol Clin North Am; 2008 Oct; 22(5):979-96, x. PubMed ID: 18954747
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
[TBL] [Abstract][Full Text] [Related]
8. Adult T-cell leukemia/lymphoma clinically confused with viral/drug skin eruptions and pathologically misinterpreted as mycosis fungoides/Sézary syndrome.
AbdullGaffar B; Abdulrahman S
J Cutan Pathol; 2021 Sep; 48(9):1103-1108. PubMed ID: 33354782
[TBL] [Abstract][Full Text] [Related]
9. Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.
Trager MH; de Clippelé D; Ram-Wolff C; de Masson A; Vignon-Pennamen MD; Battistella M; Michel L; Bagot M; Dobos G
Acta Derm Venereol; 2020 May; 100(10):adv00158. PubMed ID: 32449779
[TBL] [Abstract][Full Text] [Related]
10. Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai J; Almazan TH; Hong EK; Khodadoust MS; Arai S; Weng WK; Kim YH
JAMA Dermatol; 2018 Jun; 154(6):728-730. PubMed ID: 29800117
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
13. Adult T-cell leukemia/lymphoma and cutaneous T-cell lymphoma. Are they related?
Yamada M; Takigawa M; Iwatsuki K; Inoue F
Int J Dermatol; 1989 Mar; 28(2):107-13. PubMed ID: 2786860
[TBL] [Abstract][Full Text] [Related]
14. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
Safai B
Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
[No Abstract] [Full Text] [Related]
16. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
17. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis.
Wada DA; Wilcox RA; Weenig RH; Gibson LE
J Cutan Pathol; 2010 May; 37(5):535-41. PubMed ID: 19674197
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
19. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
Ito A; Sugita K; Adachi K; Hosoda Y; Motokura T; Yamamoto O
Acta Derm Venereol; 2017 Mar; 97(3):377-378. PubMed ID: 27786349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
